Financial Comparison
Abbott Laboratories vs Boston Scientific Corporation
Click a ticker to view the full analysis.
In short
Abbott Laboratories is the more profitable of the two, keeping 14.7% of revenue as net profit against 14.4% for Boston Scientific Corporation. Abbott Laboratories trades at the higher trailing P/E (31.9× vs 17.0× for Boston Scientific Corporation), so investors pay more for each dollar of its earnings. Fisclear flags 1 medium- or high-severity risk for Abbott Laboratories and 1 for Boston Scientific Corporation.
Based on filings for periods ending 30 Jun 2026 (ABT) and 30 Jun 2026 (BSX) · Updated
FisclearScore Comparison
FisclearScore is a quantitative model. ABT shown solid · BSX shown dashed. Not financial advice.
| Metric | ABT | BSX |
|---|---|---|
| Price | $98.49 | $42.04 |
| Market Cap | $171.6B | $60.9B |
| P/E (TTM) | 31.9x | 17.0x |
| P/B | 3.3x | 2.4x |
| Beta | 0.58 | 0.57 |
| Div Yield | 2.48% | 0.00% |
| Revenue (TTM) | $44.3B | $20.1B |
| Net Income | $6.5B | $2.9B |
| Gross Margin | — | 69.0% |
| Risk Flags | 1 flag | 1 flag |
Related comparisons
Data sourced from SEC EDGAR, Yahoo Finance, and official exchange filings. For informational purposes only. Not financial advice.